Hints and tips:
...It repeated this success with its Covid treatments and could do so again with its new drugs, said Louise Chen, analyst at Cantor Fitzgerald....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...It was made by US pharmaceutical giant Pfizer and Germany's BioNTech....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Interim data have shown that its vaccine has an efficacy rate up there with the shots developed by BioNTech/Pfizer and Moderna, based on revolutionary messengerRNA technology....
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
James Blitz and Ravi Mattu on the battle over phone security
...John FitzGerald, research professor at the Economic and Social Research Institute, says the focus on tax misses many of the reasons why companies have based themselves in Ireland....
The FT debates Pfizer's takeover bid for AstraZeneca
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...“Despite the near-term headwind from lost tobacco sales, management guided very strongly for [the first quarter],” Cantor Fitzgerald analyst Ajay Jain said....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...He no longer owns Idol and five years ago sold his company, 19 Entertainment, to media group CKX Inc....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...Marc Pado, chief investment strategist at Cantor Fitzgerald, said the market could continue to rally in spite of Tuesday’s falls....
...“This is exactly what the market wanted to see”, said Marc Pado, chief market strategist at Cantor Fitzgerald....
...Its supply chain services business, where it acts as exclusive agents for leading international drugmakers such as Pfizer, contributed net profits of €9.6m, up from €7.6m....
...Michael Ryan, lawyer with McCann Fitzgerald, says by locating in a low-tax jurisdiction, a company is able to limit the tax its offshore subsidiaries pay when remitted as dividends....
...Pfizer’s quarterly profit fell 48 per cent, hurt by restructuring costs and weaker-than-expected drug sales....
...Healthcare stocks Merck , down 1.3 per cent at $52.71, and Pfizer , off 0.5 per cent at $27.41, both weighed on the blue-chip benchmark....
...“The market has concerns about inflation and the risk of a recession” said Marc Pado, chief market strategist at Cantor Fitzgerald....
International Edition